Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
2.
Orphanet J Rare Dis ; 19(1): 129, 2024 Mar 21.
Article in English | MEDLINE | ID: mdl-38515174

ABSTRACT

BACKGROUND: Advancements in genetic testing have led to Usher syndrome now being diagnosed at a much earlier age than in the past, enabling the provision of early intervention and support to children and families. Despite these developments, anecdotal reports suggest there are substantial gaps in the services and supports provided to parents of children with Usher syndrome. The current study investigated the support needs of parents of children with Usher syndrome Type 1 when their child was aged 0 to 5 years. METHOD: Purposive sampling was used, and six semi-structured interviews were conducted with Australian parents of children with Usher syndrome, Type 1. Data was analysed using modified reflexive thematic analysis. RESULTS: Four key themes were identified as being central to the support needs of parents of children with Usher syndrome aged 0 to 5 years. (1) Social Needs referred to parents' need for various sources of social support, (2) Informational Needs described the lack of information parents received regarding Usher syndrome from treating professionals, (3) Practical Needs included supports needed to assist parents in managing the day-to-day tasks of caring for a child with a disability, and (4) Emotional Needs represented the emotional support (both formal and informal) that parents needed to be a positive support to their child. CONCLUSIONS: Findings provide rich information for relevant support groups, policy makers, individual healthcare professionals, and professional governing bodies regarding the education of stakeholders and the development and implementation of best-practice treatment guidelines.


Subject(s)
Usher Syndromes , Child , Humans , Child, Preschool , Usher Syndromes/genetics , Australia , Parents/psychology , Social Support , Health Personnel , Qualitative Research
3.
J Matern Fetal Neonatal Med ; 29(4): 582-9, 2016.
Article in English | MEDLINE | ID: mdl-25694256

ABSTRACT

AIM: Circulating immune cell activation is associated with worse outcome in adult and animal models of brain injury. Our aim was to profile the systemic inflammatory response over the first week of life in infants at risk of neonatal encephalopathy and correlate early neutrophil and monocyte endotoxin and activation responses with outcome. METHODS: Prospective observational study in a tertiary referral university hospital including 22 infants requiring resuscitation at birth who had serial (five time points) neutrophil and monocyte CD11b (marker of cell adhesion) (intracellular Reactive oxygen intermediates) ROI (cell activation), and Toll-like receptor (endotoxin recognition) before and after endotoxin stimulation ex vivo compared to neonatal controls. RESULTS: All neonates requiring resuscitation at delivery (n = 122 samples) had higher neutrophil and monocyte CD11b and TLR-4 expressions compared with adults and neonatal controls. Neonates with abnormal neuroimaging and/or severe neonatal encephalopathy had increased CD11b, ROI and TLR-4. Increased PMN TLR-4 expression was associated with increased mortality in infants with neonatal encephalopathy (NE). CONCLUSION: Innate immune dysregulation in the first week of life is associated with severity of outcome in neonatal brain injury in this cohort and may be amenable to immunomodulation.


Subject(s)
Brain Injuries/metabolism , Monocytes/metabolism , Neutrophil Activation , Neutrophils/metabolism , Adult , CD11b Antigen/metabolism , Case-Control Studies , Delivery, Obstetric , Female , Humans , Infant, Newborn , Male , Prospective Studies , Reactive Oxygen Species/metabolism , Resuscitation , Toll-Like Receptor 4/metabolism
4.
Clin Exp Immunol ; 179(3): 477-84, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25204207

ABSTRACT

Infection and inflammation can be antecedents of neonatal encephalopathy (NE) and increase the risk of neurological sequelae. Activated protein C (APC) has anti-coagulant and anti-inflammatory effects and provides neuroprotection in brain and spinal cord injury. We examined neutrophil and monocyte responses to lipopolysaccharide (LPS) in infants with NE compared with healthy adult and neonatal controls, and also studied the effect of APC. Whole blood was incubated with LPS and APC and Toll-like receptor (TLR)-4 (LPS recognition), CD11b expression (activation) and intracellular reactive oxygen intermediate (ROI; function) release from neutrophils and monocytes was examined by flow cytometry serially from days 1 to 7. We found a significant increase in neutrophil ROI in infants with NE on day 3 following LPS compared to neonatal controls and this augmented response was reduced significantly by APC. Neutrophil and monocyte CD11b expression was increased significantly on day 1 in infants with NE compared to neonatal controls. LPS-induced neutrophil TLR-4 expression was increased significantly in infants with NE on days 3 and 7 and was reduced by APC. LPS-induced monocyte TLR-4 was increased significantly in infants with NE on day 7. Neutrophil and monocyte activation and production of ROIs may mediate tissue damage in infants with NE. APC modified LPS responses in infants with NE. APC may reduce the inflammatory responses in NE and may ameliorate multi-organ dysfunction. Further study of the immunomodulatory effects of protein C may be warranted using mutant forms with decreased bleeding potential.


Subject(s)
Anticoagulants/pharmacology , Brain/drug effects , Inflammation/drug therapy , Mental Retardation, X-Linked/drug therapy , Monocytes/drug effects , Neutrophils/drug effects , Protein C/pharmacology , Adult , Brain/pathology , CD11b Antigen/genetics , CD11b Antigen/metabolism , Cells, Cultured , Female , Humans , Infant, Newborn , Inflammation/immunology , Lipopolysaccharides/immunology , Male , Mental Retardation, X-Linked/immunology , Monocytes/immunology , Neuroprotective Agents , Neutrophils/immunology , Reactive Oxygen Species/metabolism , Toll-Like Receptor 4/genetics , Toll-Like Receptor 4/metabolism , Up-Regulation/drug effects , Young Adult
6.
Eye (Lond) ; 23(12): 2194-9, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19182767

ABSTRACT

PURPOSE: To investigate the effect of topical prostaglandin analogue use on the efficacy of selective laser trabeculoplasty (SLT) intraocular pressure (IOP) lowering in patients with open-angle glaucoma. PATIENTS AND METHODS: This retrospective study included 123 consecutive patients who underwent 180 degrees SLT for the first time. Eyes were grouped into those that received prostaglandin analogues before and after SLT (n=74) and those that did not (n=49). The main outcome measure was IOP lowering after SLT. Success was defined as > or =20% reduction in IOP without further glaucoma intervention. RESULTS: There was no significant difference in IOP lowering at 6 months post-laser between the prostaglandin and non-prostaglandin groups (3.9+/-4.8 vs 4.6+/-3.6 mm Hg, P=0.43). Long-term SLT success rates were also not significantly different between the treatment groups (Kaplan-Meier survival analysis, P=0.68). IOP lowering at 6 months was similar in eyes that received no glaucoma medications, monotherapy with or without a prostaglandin analogue, or combination therapy with or without prostaglandin analogues (P=0.81). Logistic regression analysis showed that various patient characteristics including age, sex, type of glaucoma, previous glaucoma surgery, and other glaucoma risk factors did not predict a successful SLT outcome. However, higher pre-operative IOP was found to predict SLT success (odds ratio=1.12, 95% CI=1.02-1.24, P=0.02). CONCLUSION: The IOP lowering efficacy of SLT is not influenced by the use of topical prostaglandin analogues.


Subject(s)
Antihypertensive Agents/therapeutic use , Glaucoma, Open-Angle/drug therapy , Prostaglandins/therapeutic use , Trabecular Meshwork/surgery , Trabeculectomy/methods , Administration, Topical , Amides/therapeutic use , Bimatoprost , Cloprostenol/analogs & derivatives , Cloprostenol/therapeutic use , Glaucoma, Open-Angle/physiopathology , Glaucoma, Open-Angle/surgery , Humans , Intraocular Pressure/drug effects , Intraocular Pressure/physiology , Kaplan-Meier Estimate , Laser Therapy , Latanoprost , Logistic Models , Outcome Assessment, Health Care , Prostaglandins F, Synthetic/therapeutic use , Retrospective Studies , Risk Factors , Travoprost
SELECTION OF CITATIONS
SEARCH DETAIL
...